# US 2026/0242336 A1 · Composition for preventing or treating cancer diseases comprising aryl-piperidine derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242336 A1
- Document ID: US20260242336A1
- Status: Published application
- Kind: A1
- Application number: 19/152,508
- Filed: 2024-02-01
- Published: 2026-08-20
- Earliest claimed: 2023-02-02
- Assignees: Korea Research Institute of Chemical Technology; Korea Institute of Radiological & Medical Sciences
- Applicants: Korea Research Institute of Chemical Technology; Korea Institute of Radiological & Medical Sciences
- Inventors: Ji-Yeon AHN; Hwani RYU; Hye-Ran SEO; Hyo Jeong KIM; Jae-Sung KIM; Jieyoung SONG; Sang Gu HWANG; In Su JUNG; Juhan LEE; Kwan-Young JEONG; Kyu Myung LEE
- Web page: https://patentgrep.com/patent/US20260242336A1

## CPC

- C07D 211/74: Oxygen atoms
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/113: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/58: attached in position 4
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for treating or preventing tankyrase-related cancer diseases comprising an aryl-piperidine derivative compound or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition inhibits tankyrase (TNKS) enzymatic activity, inhibits β-catenin target gene expression and active β-catenin protein expression, stabilizes AXIN2 protein levels, and exhibits anticancer activity in cancer cell lines, such that the compound can be used as an anticancer agent, and cause a synergistic effect in combination therapy with other anticancer agents.

## Claims

### Claim 1

An aryl-piperidine derivative compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:
wherein, in the Chemical Formula 1,
R1 to R3 are the same or different and are each independently selected from hydrogen (H), nitro (NO2), and cyano (CN),
R4 is any one selected from
E1 to E8 are the same or different and are each independently CH or N,
R′ is hydrogen (H) or (C1~C4)alkyl, and
n is any one of 1 to 5.

### Claim 2 (depends on 1)

The aryl-piperidine derivative compound of claim 1, wherein, in the Chemical Formula 1, R2 is hydrogen (H) or nitro (NO2), R4 is any one of
E1 is N, E3 to E3 and E5 are CH, R′ is hydrogen (H) or methyl, and n is any one of 1 to 3.

### Claim 3 (depends on 1)

The aryl-piperidine derivative compound of claim 1, wherein
the aryl-piperidine derivative compound is selected from the group consisting of N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-2-(1-(2-cyanophenyl)piperidin-4-yl)acetamide, 2-(1-(2-cyanophenyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)acetamide, 2-(1-(2-cyanophenyl)piperidin-4-yl)-N-(imidazo[1,2-a]pyridin-3-yl)acetamide, 2-(1-(2-cyanophenyl)piperidin-4-yl)-N-(imidazo[1,2-a]pyridin-5-yl)acetamide, N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-3-(1-(2-cyanophenyl)piperidin-4-yl)propanamide, N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(1-(2-cyanophenyl)piperidin-4-yl)butanamide, 3-(1-(2-cyanophenyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)propanamide, 3-(1-(2-cyanophenyl)piperidin-4-yl)-N-(imidazo[1,2-a]pyridin-3-yl)propanamide, 3-(1-(2-cyanophenyl)piperidin-4-yl)-N-(imidazo[1,2-a]pyridin-5-yl)propanamide, 3-(1-(2-cyanophenyl)piperidin-4-yl)-N-(1-methyl-1H-indol-6-yl)propanamide, 3-(1-(2-cyanophenyl)piperidin-4-yl)-N-(1H-indol-4-yl)propanamide, 3-(1-(2-cyanophenyl)piperidin-4-yl)-N-(1H-indol-7-yl)propanamide, N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-3-(1-(2-nitrophenyl)piperidin-4-yl)propanamide, N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-3-(1-(3-nitrophenyl)piperidin-4-yl)propanamide, N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-3-(1-(4-nitrophenyl)piperidin-4-yl)propanamide, N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-3-(1-(4-cyanophenyl)piperidin-4-yl)propanamide, and N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-3-(1-(2,4-dinitrophenyl)piperidin-4-yl)propanamide.

### Claim 4 (depends on 1)

The aryl-piperidine derivative compound of claim 1, wherein, in the Chemical Formula 1, R1 is cyano (CN), R2 and R3 are hydrogen (H), R4 is
E1, E6, and E7 are N, E2 to E5 and E8 are CH, and n is 1 or 2.

### Claim at position 5

5-8. (canceled)

### Claim 9

A method of treating or preventing a tankyrase-related cancer disease, comprising:
administering a pharmaceutical composition comprising an aryl-piperidine derivative compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof to a subject,
[Chemical Formula 1]
wherein, in the Chemical Formula 1,
R1 to R3 are the same or different and are each independently selected from hydrogen (H), nitro (NO2), and cyano (CN),
R4 is any one selected from
E1 to E8 are the same or different and are each independently CH or N,
R′ is hydrogen (H) or (C1~C4)alkyl, and
n is any one of 1 to 5.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cancer disease is selected from the group consisting of colon cancer, lung cancer, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, breast cancer, stomach cancer, liver cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, breast cancer, brain cancer, laryngeal cancer, prostate cancer, bladder cancer, esophagus cancer, thyroid cancer, kidney cancer, blood cancer, and rectal cancer.

### Claim 11

A method for combination therapy for treating a tankyrase-related cancer disease, comprising:
administering a pharmaceutical composition comprising an aryl-piperidine derivative compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof and an anticancer agent to a subject,
wherein, in the Chemical Formula 1,
R1 to R3 are the same or different and are each independently selected from hydrogen (H), nitro (NO2), and cyano (CN),
R4 is any one selected from
E1 to E8 are the same or different and are each independently CH or N,
R′ is hydrogen (H) or (C1~C4)alkyl, and
n is any one of 1 to 5.

### Claim 12 (depends on 11)

The method of claim 11, wherein the anticancer agent is selected from the group consisting of 7-ethyl-10-hydroxycamptothecin, 5-fluorouracil, cisplatin, paclitaxel, doxorubicin, daunorubicin, vinblastine, vincristine, actinomycin D, teniposide, etoposide, cyclophosphamide, epirubicin, adriamycin, daunomycin, and mitomycin-C.

### Claim 13 (depends on 11)

The method of claim 11, wherein the cancer disease is selected from the group consisting of colon cancer, lung cancer, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, breast cancer, stomach cancer, liver cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, breast cancer, brain cancer, laryngeal cancer, prostate cancer, bladder cancer, esophagus cancer, thyroid cancer, kidney cancer, blood cancer, and rectal cancer.

### Claim at position 11

14-17. (canceled)
